Shares of Five Prime Therapeutics Inc. (NASDAQ:FPRX) were up 2.9% during trading on Thursday . The stock traded as high as $44.55 and last traded at $43.98, with a volume of 173,659 shares. The stock had previously closed at $42.73.

Several analysts recently commented on FPRX shares. Zacks Investment Research raised Five Prime Therapeutics from a “hold” rating to a “buy” rating and set a $46.00 price objective on the stock in a research note on Tuesday, April 5th. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Five Prime Therapeutics in a research note on Tuesday. Oppenheimer Holdings Inc. reaffirmed a “buy” rating on shares of Five Prime Therapeutics in a research note on Monday, April 18th. Jefferies Group reaffirmed a “buy” rating on shares of Five Prime Therapeutics in a research note on Sunday, May 8th. Finally, BMO Capital Markets started coverage on Five Prime Therapeutics in a research note on Tuesday, April 12th. They set a “market perform” rating and a $50.00 price objective on the stock. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $45.80.

The stock has a market capitalization of $1.17 billion and a PE ratio of 4.89. The stock has a 50-day moving average price of $42.46 and a 200-day moving average price of $39.40.

Five Prime Therapeutics (NASDAQ:FPRX) last posted its earnings results on Thursday, May 5th. The company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.22. The company had revenue of $6.50 million for the quarter, compared to the consensus estimate of $5.26 million. During the same period in the previous year, the firm posted ($0.44) EPS. The business’s quarterly revenue was up 51.2% compared to the same quarter last year. On average, equities analysts forecast that Five Prime Therapeutics Inc. will post ($2.35) earnings per share for the current year.

In related news, CEO Lewis T. Williams sold 48,671 shares of the business’s stock in a transaction on Thursday, April 21st. The shares were sold at an average price of $48.05, for a total value of $2,338,641.55. Following the sale, the chief executive officer now owns 341,078 shares of the company’s stock, valued at $16,388,797.90. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Marc Belsky sold 34,102 shares of the business’s stock in a transaction on Friday, April 22nd. The stock was sold at an average price of $50.00, for a total transaction of $1,705,100.00. Following the completion of the sale, the chief financial officer now directly owns 88,410 shares in the company, valued at approximately $4,420,500. The disclosure for this sale can be found here.

Other hedge funds have modified their holdings of the company. ProShare Advisors LLC boosted its stake in shares of Five Prime Therapeutics by 16.9% in the fourth quarter. ProShare Advisors LLC now owns 25,418 shares of the company’s stock valued at $1,055,000 after buying an additional 3,682 shares in the last quarter. Oxford Asset Management acquired a new stake in shares of Five Prime Therapeutics during the fourth quarter valued at $1,241,000. Russell Frank Co acquired a new stake in shares of Five Prime Therapeutics during the fourth quarter valued at $1,265,000. EAM Investors LLC acquired a new stake in shares of Five Prime Therapeutics during the fourth quarter valued at $1,549,000. Finally, California State Teachers Retirement System boosted its stake in shares of Five Prime Therapeutics by 7.3% in the fourth quarter. California State Teachers Retirement System now owns 42,025 shares of the company’s stock valued at $1,744,000 after buying an additional 2,842 shares in the last quarter.

Five Prime Therapeutics, Inc (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.